|
Defendor: Real-world evidence of primary prolonged G-CSF prophylaxis by empegfilgrastim for relative dose intensity compliance in patients with solid tumors—The primary analysis. |
|
|
Honoraria - BIOCAD; Novartis |
Consulting or Advisory Role - BIOCAD; Novartis |
|
|
No Relationships to Disclose |
|
|
Research Funding - BIOCAD |
|
|
Honoraria - AstraZeneca; BIOCAD; BMS Brazil; Roche |
Research Funding - BIOCAD |
|
|
Research Funding - BIOCAD |
|
|
Research Funding - BIOCAD |
|
|
Research Funding - Biocad |
|
|
No Relationships to Disclose |
|
|
Honoraria - AstraZeneca; BIOCAD; Roche |
Research Funding - BIOCAD |
Travel, Accommodations, Expenses - AstraZeneca; Roche |
|
|
Honoraria - AstraZeneca; BIOCAD; Roche |
Research Funding - BIOCAD; Novartis |
Travel, Accommodations, Expenses - AstraZeneca; Roche |
|
|
Honoraria - AstraZeneca; BIOCAD; Bristol-Myers Squibb; Roche |
Research Funding - BIOCAD |
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; Roche |
|
|
No Relationships to Disclose |
|
|
|
Research Funding - BIOCAD |
Travel, Accommodations, Expenses - AstraZeneca; Roche |
|
|
Honoraria - AstraZeneca; BIOCAD; Novartis; Roche |
Research Funding - AstraZeneca; BIOCAD; Novartis; Roche |
|
|
Honoraria - AstraZeneca; BIOCAD; Bristol-Myers Squibb; Merck; Novartis; Roche |
Research Funding - BIOCAD |
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; Merck; Novartis; Roche |
|
|
Honoraria - BIOCAD; Novartis |
|
|
No Relationships to Disclose |